SCENESSE® (afamelanotide 16mg)
Erythropoietic Protoporphyria (EPP)
ApprovedCommercial
Key Facts
Indication
Erythropoietic Protoporphyria (EPP)
Phase
Approved
Status
Commercial
Company
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals is a global leader in photomedicine, translating scientific expertise in melanocortins into therapeutic and cosmetic solutions. The company's core focus is on developing treatments for severe photodermatoses, vitiligo, and exploring applications in DNA repair and central nervous system disorders. With a commercial-stage product generating record revenues, Clinuvel is strategically expanding its pipeline and luxury skincare division, PhotoCosmetics, to leverage its proprietary science across multiple markets.
View full company profile